<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01502956</url>
  </required_header>
  <id_info>
    <org_study_id>PFDN 20</org_study_id>
    <secondary_id>U01HD069031</secondary_id>
    <nct_id>NCT01502956</nct_id>
  </id_info>
  <brief_title>Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)</brief_title>
  <acronym>ROSETTA</acronym>
  <official_title>Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Pelvic Floor Disorders Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Pelvic Floor Disorders Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, open-label, active-control trial is to compare the
      effectiveness of intra-detrusor botulinum toxin A (Botox A®, Allergan) versus sacral
      neuromodulation (InterStim®, Medtronic) for the treatment of refractory urge urinary
      incontinence. In addition, the study will evaluate select technical attributes of the
      interventions as well as the effect of these two interventions on other lower urinary tract
      and pelvic floor symptoms.

      Hypothesis: InterStim® therapy will result in a greater reduction in daily urge urinary
      incontinence episodes over the 6-month follow-up period as compared to Botox A® injection.

      A supplemental study investigates whether biological markers including those related to
      inflammation and connective tissue remodeling change following treatments with Botox A® and
      Interstim®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Aim:

      To compare the change from baseline in the number of urge urinary incontinence episodes
      (UUIE) over 6 the six month follow-up period in women randomized to sacral neuromodulation
      (InterStim®) therapy, versus those randomized to intra-detrusor injection with 200 units of
      botulinum toxin A (Botox A®).

      Secondary Aims:

        -  Long Term Efficacy: To compare the long-term (12 and 24 month) efficacy outcomes in
           women randomized to sacral neuromodulation(InterStim®) therapy, versus those randomized
           to intra-detrusor injection with 200 units of botulinum toxin A (Botox A®). Secondary
           efficacy outcomes, collected at 12 and 24 months as well as 6 months,include adequate
           control of their urge urinary incontinence, change in bothersome symptoms of urinary
           urge incontinence (UUI), severity of urge incontinence, urinary frequency, nocturia,
           subject satisfaction with therapy, quality of life measures and bowel and sexual
           function.

        -  Cost Effectiveness: To compare utilization of medical resources for cost effectiveness
           analysis and cost-utility between treatment groups.

        -  Treatment Safety and Burden: To assess safety profile and treatment burden of both
           interventions by comparing adverse event incidence between treatment arms, and also by
           obtaining estimates of incidence of treatment-specific safety and burden outcomes.
           Safety and burden outcomes for Botox A® injections include receipt of additional
           injections and intermittent catheterization due to voiding dysfunction/partial urinary
           retention. Safety and burden outcomes for InterStim® device include infection, pain,
           lead migration, reprogramming (and reasons for) and surgical revision (and reasons for).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Urge Urinary Incontinence (UUI) Episodes</measure>
    <time_frame>6 Months</time_frame>
    <description>The primary outcome is the change from baseline in mean number of UUI episodes over the first 6-month visit period (1, 2, 3, 4, 5 and 6 month assessments); and is measured using 3-day bladder diaries administered monthly for the first 6 month visit period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improvement of Bladder Function and Urinary Leakage</measure>
    <time_frame>6 Months</time_frame>
    <description>Proportion of subjects who report adequate improvement of their bladder function and urinary leakage with the Patient Global Impression of Improvement Questionnaire (PGI-I) at 6 months. Adequate improvement is defined as a rating of 1, 2, or 3 (better) on the patient-reported measure of perceived improvement with treatment on a scale of 1 (very much better) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Overactive Bladder</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in mean Overactive Bladder Questionnaire Short Form (OABq-SF) score throughout baseline to the first 6-month visit (1, 2, 3, 4, 5, and 6-month assessments). Values range from 0 to 100 with higher scores on the symptom scale indicating greater severity of symptoms and higher scores on the quality of life scale indicating a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Frequency and Nocturia</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in mean number of urinary incontinence episodes (any type) and nocturia episodes from baseline over the first 6-month visit period (1, 2, 3, 4, 5, and 6-month assessments) as measured by the 3 day bladder diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Urge Incontinence Symptoms</measure>
    <time_frame>6 Months</time_frame>
    <description>Severity of urge incontinence symptoms at 6 month visit period as measured by the Sandvik questionnaire. The Sandvik score is a patient-reported measure of incontinence severity as assessed on a scale of slight (1-2), moderate (3-6), severe (8-9), very severe (12) to severe (10-12) using a standard scoring algorithm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction (OAB-SATq Treatment Satisfaction, Adverse Effects, Treatment Endorsement, and Convenience)</measure>
    <time_frame>6 months</time_frame>
    <description>Treatment satisfaction as measured by the mean Overactive Bladder Satisfaction of Treatment Questionnaire (OAB-SATq) score at 6 months (6 month assessment). The OAB-SATq score ranges from 0 to 100 and includes 5 subscales: treatment satisfaction, side effects, treatment endorsement, convenience, and treatment preference, with higher scores reflecting better satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction (OAB-SATq Treatment Preference)</measure>
    <time_frame>6 Months</time_frame>
    <description>Treatment preference as measured by the Overactive Bladder Satisfaction of Treatment Questionnaire (OAB-SATq) at 6 months (6 month assessment).OAB-SATq treatment preference is a binary outcome that is classified as yes if a participant answers either &quot;Slight preference for the treatment I am receiving now&quot; or &quot;Definitely prefer the treatment I am receiving now&quot; to the question &quot;Do you prefer the treatment that you received since entering this study to the treatment you received before the study?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (UDI-SF)</measure>
    <time_frame>6 Months</time_frame>
    <description>Change from baseline in quality of life measures over the first 6 month visit period (6 month assessment) as measured by the change in mean Urinary Distress Inventory Short Form (UDI-SF) score. The UDI-SF scale has a range from 0 to 100 with higher scores indicating greater distress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (IIQ-SF)</measure>
    <time_frame>6 Months</time_frame>
    <description>Change from baseline in quality of life measures over the first 6 month visit period (6 month assessment) as measured by the change in the mean Incontinence Impact Questionnaire short form (IIQ-SF) score. The IIQ-SF scale has a range from 0 to 100 with higher scores indicating a worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (HUI-3)</measure>
    <time_frame>6 Months</time_frame>
    <description>Change from baseline in quality of life measures over the first 6 month visit period (6 month assessment) as measured by the Health Utility Index, Version 3 (HUI-3). The HUI 3 scale has a range from 0 to 1 with higher scores representing better health.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">386</enrollment>
  <condition>Urinary Incontinence, Urge</condition>
  <arm_group>
    <arm_group_label>InterStim® device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/&gt;50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botox® injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InterStim® device</intervention_name>
    <description>Eligible subjects will complete baseline assessments, be randomized and scheduled for first stage lead placement (FSLP) InterStim®. The criterion for an initial clinical response to InterStim® therapy will be defined as a ≥50% improvement in the mean number of UUIE/day on a minimum 3 day bladder diary, completed during the 7-14 days following the first stage lead placement (FSLP). Subjects with a ≥ 50% improvement mean number of UUIE/day will be eligible to proceed with implantation of the implantable pulse generator (IPG). Subjects will then be followed monthly to determine the response to therapy.</description>
    <arm_group_label>InterStim® device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox® injection</intervention_name>
    <description>Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.</description>
    <arm_group_label>Botox® injection</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-pregnant adult female at least 21 years old, with no plans to become pregnant
             during the course of the trial) and if of child-bearing potential, with a negative
             pregnancy test, and if sexually active, must be using medically acceptable
             contraception.

          -  6 urge urinary incontinence episodes on a 3-day baseline bladder diary, with these
             urge incontinence episodes representing greater than 50% of the total incontinent
             episodes recorded.

          -  Willing and able to complete all study related items and interviews.

          -  Refractory urinary urge urinary incontinence: defined as (1) Persistent symptoms
             despite at least one or more conservative treatments (e.g. supervised behavioral
             therapy, supervised physical therapy); and (2)Persistent symptoms despite the use of a
             minimum of two anticholinergics, or unable to tolerate medication due to side effects,
             or has a contraindication to taking anticholinergic medication.

          -  Currently not on an anticholinergic or antimuscarinic medication (e.g. oxybutynin,
             tolterodine, and/or fesoterodine) or be willing to stop medication for 3 weeks prior
             to completing baseline bladder diary and expected to remain off medications through
             duration of study.

          -  Demonstrates ability (or have caregiver demonstrate ability) to perform clean
             intermittent self-catheterization.

          -  Grossly neurologically normal on exam and no gross systemic neurologic conditions
             believed to affect urinary function.

          -  Urodynamic assessment within the previous 18 months prior to enrollment or done after
             enrollment, prior to randomization.

        Exclusion Criteria:

          -  Neurologic diseases such as multiple sclerosis, Parkinson Disease, CVA within 6 months
             prior to enrollment, myasthenia gravis, Charcot-Marie-Tooth disease, clinically
             significant peripheral neuropathy, and complete spinal cord injury.

          -  Untreated urinary tract infection (UTI).

          -  Any prior use of either study therapy for treatment of urinary urge incontinence
             (Botox A® or Interstim®).

          -  Current participation in any other conflicting interventional research study.

          -  PVR &gt;150 ml on 2 occasions within 6 months prior to enrollment (If the PVR value was
             obtained by ultrasound and was ≥150 ml, the PVR will be confirmed by catheterization
             which will be the gold standard)

          -  Subjects with knowledge of planned MRIs or diathermy, except those allowable per
             Medtronic guidelines.

          -  Current or prior bladder malignancy.

          -  Surgically altered detrusor muscle, such as augmentation cystoplasty.

          -  Subjects taking aminoglycosides.

          -  Currently pregnant or lactating.

          -  Subjects who are on ambulatory anticoagulant therapy, including aspirin, who are
             unable to discontinue treatment for 24 hours prior to bladder injection and staged
             InterStim® procedure.

          -  Serum creatinine level greater than twice the upper limit of normal within the
             previous year prior to enrollment.

          -  Surgical treatment for stress incontinence (sling, Burch or urethral injection) or
             pelvic organ prolapse recommended or planned at enrollment by study investigator(s).

          -  Prior stress incontinence or prolapsed surgery within the last 6 months prior to
             enrollment.

          -  Allergy to lidocaine or bupivacaine.

          -  Prior pelvic radiation.

          -  Uninvestigated hematuria.

          -  Greater than or equal to Stage III vaginal prolapse.

          -  Known allergy to Botox A®.

          -  Use of a vaginal pessary.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cindy Amundsen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Holly Richter, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shawn A. Menefee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente, San Diego, CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandip Vasada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deborah L. Myers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown/Women and Infants Hospital of Rhode Island</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoko Kumesu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lily Arya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerry Lowder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W. Thomas Gregory, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis Wallace, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTI International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Meikle, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham, Department of Obstetrics and Gynecology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249-7333</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego, Women's Pelvic Medicine Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Division of Urogynecology and Reconstructive Pelvic Surgery</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>277707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, Obstretric and Gynecology and Women Health Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44194</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University, Kohler Pavilion</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univesity of Pittsburgh, Magee-Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital of Rhode Island, Center for Women's Pelvic Medicine and Reconstructive Surgery</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pfdn.rti.org</url>
    <description>Website for the Pelvic Floor Disorder Network</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2011</study_first_submitted>
  <study_first_submitted_qc>December 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2012</study_first_posted>
  <results_first_submitted>October 3, 2017</results_first_submitted>
  <results_first_submitted_qc>February 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 8, 2018</results_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory Urinary Urge Incontinence</keyword>
  <keyword>Botox A®</keyword>
  <keyword>Interstim® Device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women who have persistent severe UUI symptoms, defined as ≥6 UUI episodes on a 3-day bladder diary are recruited from urology and urogynecology subspecialty clinics as well as by other marketing methods.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>InterStim® Device</title>
          <description>The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/&gt;50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.
InterStim® device: Eligible subjects will complete baseline assessments, be randomized and scheduled for first stage lead placement (FSLP) InterStim®. The criterion for an initial clinical response to InterStim® therapy will be d</description>
        </group>
        <group group_id="P2">
          <title>Botox® Injection</title>
          <description>Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.
Botox® injection: Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>InterStim® Device</title>
          <description>The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 1st stage is lead placement into the S3 foramen with best response to stimulation.The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/&gt;50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.</description>
        </group>
        <group group_id="B2">
          <title>Botox® Injection</title>
          <description>Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="174"/>
            <count group_id="B2" value="190"/>
            <count group_id="B3" value="364"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="11.8"/>
                    <measurement group_id="B2" value="62.9" spread="11.5"/>
                    <measurement group_id="B3" value="63.0" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age =&gt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="327"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Pre-menopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Post-menopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="311"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not sure</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Recurrent UTIs</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No history of recurrent UTIs</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="315"/>
                  </measurement_list>
                </category>
                <category>
                  <title>History of recurrent UTIs</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary Incontinence Episodes Per Day</title>
          <units>Episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Total incontinence episodes per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="3.0"/>
                    <measurement group_id="B2" value="6.0" spread="3.0"/>
                    <measurement group_id="B3" value="5.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urge incontinence episodes per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="2.7"/>
                    <measurement group_id="B2" value="5.4" spread="2.7"/>
                    <measurement group_id="B3" value="5.3" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nocturia (number of night voids per day)</title>
          <units>Voids per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="1.4"/>
                    <measurement group_id="B2" value="1.7" spread="1.2"/>
                    <measurement group_id="B3" value="1.7" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Overactive Bladder Questionnaire – Short Form (OABq-SF)</title>
          <description>Values range from 0 to 100 with higher scores on the symptom scale indicating greater severity of symptoms and higher scores on the quality of life scale indicating better quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>OABq-SF Symptom Bother</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.1" spread="16.8"/>
                    <measurement group_id="B2" value="74.6" spread="19.5"/>
                    <measurement group_id="B3" value="75.3" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OABq-SF Quality of Life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" spread="21.6"/>
                    <measurement group_id="B2" value="38.2" spread="23.0"/>
                    <measurement group_id="B3" value="37.5" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary Frequency and Nocturia - Sandvik Questionnaire</title>
          <description>Patient-reported measure of incontinence severity as assessed on a scale of slight (1-2) to very severe (10-12) using the standard scoring algorithm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Slight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary Distress Inventory Short Form (UDI-SF)</title>
          <description>Values range from 0 to 100 with higher scores indicating greater distress.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="16.9"/>
                    <measurement group_id="B2" value="60.9" spread="18.3"/>
                    <measurement group_id="B3" value="60.1" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Incontinence Impact Questionnaire Short Form (IIQ-SF)</title>
          <description>Values range from 0 to 100 with higher scores indicating worse quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="25.8"/>
                    <measurement group_id="B2" value="52.7" spread="27.6"/>
                    <measurement group_id="B3" value="52.6" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Utilities Index Mark 3 (HUI-3)</title>
          <description>Values are defined such that the score for dead is 0; the score for perfect health is 1.0.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.74" spread="0.28"/>
                    <measurement group_id="B2" value="0.71" spread="0.30"/>
                    <measurement group_id="B3" value="0.73" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Urge Urinary Incontinence (UUI) Episodes</title>
        <description>The primary outcome is the change from baseline in mean number of UUI episodes over the first 6-month visit period (1, 2, 3, 4, 5 and 6 month assessments); and is measured using 3-day bladder diaries administered monthly for the first 6 month visit period.</description>
        <time_frame>6 Months</time_frame>
        <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>InterStim® Device</title>
            <description>The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 1st stage is lead placement into the S3 foramen with best response to stimulation.The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/&gt;50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.</description>
          </group>
          <group group_id="O2">
            <title>Botox® Injection</title>
            <description>Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Urge Urinary Incontinence (UUI) Episodes</title>
          <description>The primary outcome is the change from baseline in mean number of UUI episodes over the first 6-month visit period (1, 2, 3, 4, 5 and 6 month assessments); and is measured using 3-day bladder diaries administered monthly for the first 6 month visit period.</description>
          <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
          <units>UUI episodes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.25" lower_limit="-3.64" upper_limit="-2.87"/>
                    <measurement group_id="O2" value="-3.89" lower_limit="-4.26" upper_limit="-3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improvement of Bladder Function and Urinary Leakage</title>
        <description>Proportion of subjects who report adequate improvement of their bladder function and urinary leakage with the Patient Global Impression of Improvement Questionnaire (PGI-I) at 6 months. Adequate improvement is defined as a rating of 1, 2, or 3 (better) on the patient-reported measure of perceived improvement with treatment on a scale of 1 (very much better) to 7 (very much worse).</description>
        <time_frame>6 Months</time_frame>
        <population>All eligible participants who provided at least 1 postbaseline diary assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>InterStim® Device</title>
            <description>The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 1st stage is lead placement into the S3 foramen with best response to stimulation.The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/&gt;50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.</description>
          </group>
          <group group_id="O2">
            <title>Botox® Injection</title>
            <description>Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement of Bladder Function and Urinary Leakage</title>
          <description>Proportion of subjects who report adequate improvement of their bladder function and urinary leakage with the Patient Global Impression of Improvement Questionnaire (PGI-I) at 6 months. Adequate improvement is defined as a rating of 1, 2, or 3 (better) on the patient-reported measure of perceived improvement with treatment on a scale of 1 (very much better) to 7 (very much worse).</description>
          <population>All eligible participants who provided at least 1 postbaseline diary assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urinary leakage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bladder function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Overactive Bladder</title>
        <description>Change in mean Overactive Bladder Questionnaire Short Form (OABq-SF) score throughout baseline to the first 6-month visit (1, 2, 3, 4, 5, and 6-month assessments). Values range from 0 to 100 with higher scores on the symptom scale indicating greater severity of symptoms and higher scores on the quality of life scale indicating a better quality of life.</description>
        <time_frame>6 Months</time_frame>
        <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>InterStim® Device</title>
            <description>The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 1st stage is lead placement into the S3 foramen with best response to stimulation.The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/&gt;50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.</description>
          </group>
          <group group_id="O2">
            <title>Botox® Injection</title>
            <description>Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Overactive Bladder</title>
          <description>Change in mean Overactive Bladder Questionnaire Short Form (OABq-SF) score throughout baseline to the first 6-month visit (1, 2, 3, 4, 5, and 6-month assessments). Values range from 0 to 100 with higher scores on the symptom scale indicating greater severity of symptoms and higher scores on the quality of life scale indicating a better quality of life.</description>
          <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OABq-SF Symptom Bother</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.6" lower_limit="-42.5" upper_limit="-34.6"/>
                    <measurement group_id="O2" value="-46.7" lower_limit="-50.5" upper_limit="-43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OABq-SF Quality of Life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" lower_limit="34.1" upper_limit="42.0"/>
                    <measurement group_id="O2" value="41.6" lower_limit="37.9" upper_limit="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Frequency and Nocturia</title>
        <description>Change in mean number of urinary incontinence episodes (any type) and nocturia episodes from baseline over the first 6-month visit period (1, 2, 3, 4, 5, and 6-month assessments) as measured by the 3 day bladder diary.</description>
        <time_frame>6 Months</time_frame>
        <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>InterStim® Device</title>
            <description>The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 1st stage is lead placement into the S3 foramen with best response to stimulation.The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/&gt;50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.</description>
          </group>
          <group group_id="O2">
            <title>Botox® Injection</title>
            <description>Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Frequency and Nocturia</title>
          <description>Change in mean number of urinary incontinence episodes (any type) and nocturia episodes from baseline over the first 6-month visit period (1, 2, 3, 4, 5, and 6-month assessments) as measured by the 3 day bladder diary.</description>
          <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
          <units>Number of episodes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Incontinence episodes (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.50" lower_limit="-3.94" upper_limit="-3.06"/>
                    <measurement group_id="O2" value="-4.02" lower_limit="-4.44" upper_limit="-3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturia episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" lower_limit="-0.43" upper_limit="-0.10"/>
                    <measurement group_id="O2" value="-0.40" lower_limit="-0.56" upper_limit="-0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Urge Incontinence Symptoms</title>
        <description>Severity of urge incontinence symptoms at 6 month visit period as measured by the Sandvik questionnaire. The Sandvik score is a patient-reported measure of incontinence severity as assessed on a scale of slight (1-2), moderate (3-6), severe (8-9), very severe (12) to severe (10-12) using a standard scoring algorithm.</description>
        <time_frame>6 Months</time_frame>
        <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>InterStim® Device</title>
            <description>The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 1st stage is lead placement into the S3 foramen with best response to stimulation.The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/&gt;50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.</description>
          </group>
          <group group_id="O2">
            <title>Botox® Injection</title>
            <description>Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Urge Incontinence Symptoms</title>
          <description>Severity of urge incontinence symptoms at 6 month visit period as measured by the Sandvik questionnaire. The Sandvik score is a patient-reported measure of incontinence severity as assessed on a scale of slight (1-2), moderate (3-6), severe (8-9), very severe (12) to severe (10-12) using a standard scoring algorithm.</description>
          <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sandvik Slight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sandvik Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sandvik Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sandvik Very Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Satisfaction (OAB-SATq Treatment Satisfaction, Adverse Effects, Treatment Endorsement, and Convenience)</title>
        <description>Treatment satisfaction as measured by the mean Overactive Bladder Satisfaction of Treatment Questionnaire (OAB-SATq) score at 6 months (6 month assessment). The OAB-SATq score ranges from 0 to 100 and includes 5 subscales: treatment satisfaction, side effects, treatment endorsement, convenience, and treatment preference, with higher scores reflecting better satisfaction.</description>
        <time_frame>6 months</time_frame>
        <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>InterStim® Device</title>
            <description>The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 1st stage is lead placement into the S3 foramen with best response to stimulation.The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/&gt;50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.</description>
          </group>
          <group group_id="O2">
            <title>Botox® Injection</title>
            <description>Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Satisfaction (OAB-SATq Treatment Satisfaction, Adverse Effects, Treatment Endorsement, and Convenience)</title>
          <description>Treatment satisfaction as measured by the mean Overactive Bladder Satisfaction of Treatment Questionnaire (OAB-SATq) score at 6 months (6 month assessment). The OAB-SATq score ranges from 0 to 100 and includes 5 subscales: treatment satisfaction, side effects, treatment endorsement, convenience, and treatment preference, with higher scores reflecting better satisfaction.</description>
          <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OAB-SATq Treatment Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" lower_limit="55.0" upper_limit="64.7"/>
                    <measurement group_id="O2" value="67.7" lower_limit="63.2" upper_limit="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OAB-SATq Adverse Effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1" lower_limit="81.1" upper_limit="89.2"/>
                    <measurement group_id="O2" value="88.4" lower_limit="84.7" upper_limit="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OAB-SATq Endorsement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6" lower_limit="62.9" upper_limit="72.3"/>
                    <measurement group_id="O2" value="78.1" lower_limit="73.7" upper_limit="82.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OAB-SATq Convenience</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2" lower_limit="65.8" upper_limit="74.5"/>
                    <measurement group_id="O2" value="67.6" lower_limit="63.7" upper_limit="71.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Satisfaction (OAB-SATq Treatment Preference)</title>
        <description>Treatment preference as measured by the Overactive Bladder Satisfaction of Treatment Questionnaire (OAB-SATq) at 6 months (6 month assessment).OAB-SATq treatment preference is a binary outcome that is classified as yes if a participant answers either “Slight preference for the treatment I am receiving now” or “Definitely prefer the treatment I am receiving now” to the question “Do you prefer the treatment that you received since entering this study to the treatment you received before the study?”</description>
        <time_frame>6 Months</time_frame>
        <population>All eligible participants who provided at least 1 postbaseline diary assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>InterStim® Device</title>
            <description>The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 1st stage is lead placement into the S3 foramen with best response to stimulation.The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/&gt;50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.</description>
          </group>
          <group group_id="O2">
            <title>Botox® Injection</title>
            <description>Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Satisfaction (OAB-SATq Treatment Preference)</title>
          <description>Treatment preference as measured by the Overactive Bladder Satisfaction of Treatment Questionnaire (OAB-SATq) at 6 months (6 month assessment).OAB-SATq treatment preference is a binary outcome that is classified as yes if a participant answers either “Slight preference for the treatment I am receiving now” or “Definitely prefer the treatment I am receiving now” to the question “Do you prefer the treatment that you received since entering this study to the treatment you received before the study?”</description>
          <population>All eligible participants who provided at least 1 postbaseline diary assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (UDI-SF)</title>
        <description>Change from baseline in quality of life measures over the first 6 month visit period (6 month assessment) as measured by the change in mean Urinary Distress Inventory Short Form (UDI-SF) score. The UDI-SF scale has a range from 0 to 100 with higher scores indicating greater distress.</description>
        <time_frame>6 Months</time_frame>
        <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>InterStim® Device</title>
            <description>The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 1st stage is lead placement into the S3 foramen with best response to stimulation.The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/&gt;50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.</description>
          </group>
          <group group_id="O2">
            <title>Botox® Injection</title>
            <description>Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (UDI-SF)</title>
          <description>Change from baseline in quality of life measures over the first 6 month visit period (6 month assessment) as measured by the change in mean Urinary Distress Inventory Short Form (UDI-SF) score. The UDI-SF scale has a range from 0 to 100 with higher scores indicating greater distress.</description>
          <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" lower_limit="-10.9" upper_limit="-6.3"/>
                    <measurement group_id="O2" value="-10.0" lower_limit="-12.2" upper_limit="-7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (IIQ-SF)</title>
        <description>Change from baseline in quality of life measures over the first 6 month visit period (6 month assessment) as measured by the change in the mean Incontinence Impact Questionnaire short form (IIQ-SF) score. The IIQ-SF scale has a range from 0 to 100 with higher scores indicating a worse quality of life.</description>
        <time_frame>6 Months</time_frame>
        <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>InterStim® Device</title>
            <description>The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 1st stage is lead placement into the S3 foramen with best response to stimulation.The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/&gt;50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.</description>
          </group>
          <group group_id="O2">
            <title>Botox® Injection</title>
            <description>Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (IIQ-SF)</title>
          <description>Change from baseline in quality of life measures over the first 6 month visit period (6 month assessment) as measured by the change in the mean Incontinence Impact Questionnaire short form (IIQ-SF) score. The IIQ-SF scale has a range from 0 to 100 with higher scores indicating a worse quality of life.</description>
          <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" lower_limit="-13.0" upper_limit="-7.8"/>
                    <measurement group_id="O2" value="-12.4" lower_limit="-14.9" upper_limit="-9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (HUI-3)</title>
        <description>Change from baseline in quality of life measures over the first 6 month visit period (6 month assessment) as measured by the Health Utility Index, Version 3 (HUI-3). The HUI 3 scale has a range from 0 to 1 with higher scores representing better health.</description>
        <time_frame>6 Months</time_frame>
        <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>InterStim® Device</title>
            <description>The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 1st stage is lead placement into the S3 foramen with best response to stimulation.The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/&gt;50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.</description>
          </group>
          <group group_id="O2">
            <title>Botox® Injection</title>
            <description>Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (HUI-3)</title>
          <description>Change from baseline in quality of life measures over the first 6 month visit period (6 month assessment) as measured by the Health Utility Index, Version 3 (HUI-3). The HUI 3 scale has a range from 0 to 1 with higher scores representing better health.</description>
          <population>All eligible participants who provided at least 1 post-baseline diary assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" lower_limit="-0.025" upper_limit="0.013"/>
                    <measurement group_id="O2" value="-0.011" lower_limit="-0.028" upper_limit="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reported Adverse Events (AEs) include events starting on or after day 0 and on or before 6-month visit.</time_frame>
      <desc>If a subject experienced more than 1 of a given AE, the subject is counted only once for that AE.</desc>
      <group_list>
        <group group_id="E1">
          <title>InterStim® Device</title>
          <description>The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 1st stage is lead placement into the S3 foramen with best response to stimulation.The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/&gt;50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.</description>
        </group>
        <group group_id="E2">
          <title>Botox® Injection</title>
          <description>Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Intestinal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Oesophageal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Device deployment issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Medical device site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Clostridium difficile sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Carotid artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Tongue injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cyst aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Obliterative bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Sexual abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Anal sphincterotomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cardiac operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Endotracheal intubation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hernia hiatus repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Intestinal resection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Mammoplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Medical device change</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Skin graft</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Tenotomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="28" subjects_affected="20" subjects_at_risk="178"/>
                <counts group_id="E2" events="107" subjects_affected="66" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marie Gantz</name_or_title>
      <organization>RTI International</organization>
      <phone>919-597-5110</phone>
      <email>mgantz@rti.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

